PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. / Zandi, Roza; Selivanova, Galina; Christensen, Camilla Laulund; Gerds, Thomas Alexander; Willumsen, Berthe Marie; Poulsen, Hans Skovgaard.
I: Clinical Cancer Research, Bind 17, Nr. 9, 01.05.2011, s. 2830-2841.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53
AU - Zandi, Roza
AU - Selivanova, Galina
AU - Christensen, Camilla Laulund
AU - Gerds, Thomas Alexander
AU - Willumsen, Berthe Marie
AU - Poulsen, Hans Skovgaard
N1 - ©2011 AACR.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Small cell lung cancer (SCLC) is a highly malignant disease with poor prognosis, necessitating the need to develop new and efficient treatment modalities. PRIMA-1(Met) (p53-dependent reactivation of massive apoptosis), also known as APR-246, is a small molecule, which restores tumor suppressor function to mutant p53 and induces cancer cell death in various cancer types. Since p53 is mutated in more than 90% of SCLC, we investigated the ability of PRIMA-1(Met) to induce apoptosis and inhibit tumor growth in SCLC with different p53 mutations.
AB - Small cell lung cancer (SCLC) is a highly malignant disease with poor prognosis, necessitating the need to develop new and efficient treatment modalities. PRIMA-1(Met) (p53-dependent reactivation of massive apoptosis), also known as APR-246, is a small molecule, which restores tumor suppressor function to mutant p53 and induces cancer cell death in various cancer types. Since p53 is mutated in more than 90% of SCLC, we investigated the ability of PRIMA-1(Met) to induce apoptosis and inhibit tumor growth in SCLC with different p53 mutations.
U2 - 10.1158/1078-0432.CCR-10-3168
DO - 10.1158/1078-0432.CCR-10-3168
M3 - Journal article
C2 - 21415220
VL - 17
SP - 2830
EP - 2841
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 9
ER -
ID: 33923684